Literature DB >> 21134340

HIV infection is associated with reduced serum alpha-1-antitrypsin concentrations.

Courtney L Bryan1, K Scott Beard, Gregory B Pott, Jeremy Rahkola, Edward M Gardner, Edward N Janoff, Leland Shapiro.   

Abstract

PURPOSE: Several observations suggest the presence of HIV-suppressive factors in the fluid phase of blood. Alpha-1-antitrypsin (AAT), the most abundant serine protease inhibitor in the circulation, has potent anti-HIV activity in vitro, and may function as an endogenous HIV suppressor. Therefore, we assessed serum AAT concentrations for association with HIV infection.
METHODS: In this cross-sectional study, serum AAT concentrations were measured in 66 persons with HIV infection and in 45 healthy persons (Controls). In the HIV-infected group, antiretroviral therapy (ART) use was assessed and CD4+ T cell levels and plasma HIV RNA were quantified.
RESULTS: Median AAT concentration was significantly lower in the HIV-infected group (1.64 mg/mL) in comparison with Controls (1.94 mg/mL; p=0.001). AAT reduction was most pronounced in the HIV-infected subgroup with CD4+ T cell levels > 200 cells/µL in comparison with Controls (p < 0.01). Serum AAT concentrations < 1.0 mg/mL are clinically significant, and concentrations below this level were identified in 4.5% of the HIV-infected group and in no Control subjects. No association between AAT levels and viral load or use of ART was observed in HIV-infected subjects.
CONCLUSION: The association between reduced serum AAT concentration and HIV infection is consistent with a role for AAT as an endogenous HIV suppressor.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21134340     DOI: 10.25011/cim.v33i6.14589

Source DB:  PubMed          Journal:  Clin Invest Med        ISSN: 0147-958X            Impact factor:   0.825


  8 in total

1.  Impact of HIV infection on α1-antitrypsin in the lung.

Authors:  Sarah E Stephenson; Carole L Wilson; Kristina Crothers; Engi F Attia; Cherry Wongtrakool; Irina Petrache; Lynn M Schnapp
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-12-14       Impact factor: 5.464

Review 2.  Expanding the clinical indications for α(1)-antitrypsin therapy.

Authors:  Eli C Lewis
Journal:  Mol Med       Date:  2012-09-07       Impact factor: 6.354

3.  Low-density lipoprotein receptor-related protein 1 mediates α1-antitrypsin internalization in CD4+ T lymphocytes.

Authors:  Xueyuan Zhou; Zhu Liu; Leland Shapiro; Jun Yang; Gregory F Burton
Journal:  J Leukoc Biol       Date:  2015-07-23       Impact factor: 4.962

Review 4.  Alpha-1 Antitrypsin Investigations Using Animal Models of Emphysema.

Authors:  Kevin Ni; Karina A Serban; Chanan Batra; Irina Petrache
Journal:  Ann Am Thorac Soc       Date:  2016-08

5.  Increased risk of radiographic emphysema in HIV is associated with elevated soluble CD14 and nadir CD4.

Authors:  Engi F Attia; Kathleen M Akgün; Cherry Wongtrakool; Matthew Bidwell Goetz; Maria C Rodriguez-Barradas; David Rimland; Sheldon T Brown; Guy W Soo Hoo; Joon Kim; Patty J Lee; Lynn M Schnapp; Amir Sharafkhaneh; Amy C Justice; Kristina Crothers
Journal:  Chest       Date:  2014-12       Impact factor: 9.410

6.  Alpha-1-antitrypsin interacts with gp41 to block HIV-1 entry into CD4+ T lymphocytes.

Authors:  Xueyuan Zhou; Zhu Liu; Jun Zhang; Joseph W Adelsberger; Jun Yang; Gregory F Burton
Journal:  BMC Microbiol       Date:  2016-07-29       Impact factor: 3.605

Review 7.  Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19.

Authors:  Xiyuan Bai; Joseph Hippensteel; Alida Leavitt; James P Maloney; David Beckham; Cindy Garcia; Qing Li; Brian M Freed; Diane Ordway; Robert A Sandhaus; Edward D Chan
Journal:  Med Hypotheses       Date:  2020-11-12       Impact factor: 1.538

8.  In vivo anti-HIV activity of the heparin-activated serine protease inhibitor antithrombin III encapsulated in lymph-targeting immunoliposomes.

Authors:  Mohammed Asmal; James B Whitney; Corinne Luedemann; Angela Carville; Robert Steen; Norman L Letvin; Ralf Geiben-Lynn
Journal:  PLoS One       Date:  2012-11-02       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.